Patient assistance directory
Manufacturer savings and support pages for the 50 specialty drugs with the highest Medicare Part D and Medicaid spending, and independent foundations. Links and page titles exactly as each page showed them on the date checked. ClinDose does not copy eligibility rules, amounts or phone numbers; open the program's page for those.
Independent foundations
HealthWell Foundation
Page title: "Diseases and Medications - HealthWell Foundation"
Checked 2026-11-06. Each foundation lists which disease funds are open; funds open and close during the year.
Good Days
Page title: "Home - MyGoodDays.org"
Checked 2026-11-06. Each foundation lists which disease funds are open; funds open and close during the year.
CancerCare Co-Payment Assistance Foundation
Page title: "CancerCare Co-Payment Assistance Foundation | CancerCare"
Checked 2026-11-06. Each foundation lists which disease funds are open; funds open and close during the year.
Manufacturer programs by drug
1. Adalimumab · $10.3 billion combined spending
- Product website printed on the label (www.humira.com) · page title "HUMIRA® (adalimumab) - A Biologic Medication" (checked 2026-11-06)
- Cost & Savings · page title "HUMIRA® (adalimumab) Cost & Savings" (checked 2026-11-06)
- Learn about savings · page title "Ways to Save on HUMIRA® (adalimumab) - HUMIRA Complete" (checked 2026-11-06)
2. Lenalidomide · $7.2 billion combined spending
The label does not print a product website ClinDose could check. Ask the manufacturer or the specialty pharmacy about assistance, or see the foundations above.
3. Bictegravir, emtricitabine, and tenofovir alafenamide · $6.7 billion combined spending
- Product website printed on the label (www.biktarvy.com) · page title "BIKTARVY® | A One-Pill, Once-a-Day HIV Treatment Option" (checked 2026-11-06)
4. Dupilumab · $4.9 billion combined spending
- Product website printed on the label (www.dupixent.com) · page title "Take Action With DUPIXENT® (dupilumab)" (checked 2026-11-06)
- Copay Offer · page title "DUPIXENT MyWay® Copay Card & Insurance | DUPIXENT® (dupilumab)" (checked 2026-11-06)
- Patient Support Program · page title "DUPIXENT MyWay® Support for Patients | DUPIXENT® (dupilumab)" (checked 2026-11-06)
5. Etanercept · $4.3 billion combined spending
- Product website printed on the label (www.enbrel.com) · page title "ENBREL® (etanercept) | Official Patient Site" (checked 2026-11-06)
- ENBREL Co-Pay Card · page title "Financial Support and Patient Resources | ENBREL® (etanercept)" (checked 2026-11-06)
- AmgenSupportPlus.com/copay-terms · page title "Amgen® SupportPlus Co-Pay Card Terms & Conditions" (checked 2026-11-06)
6. Enzalutamide · $3.6 billion combined spending
- Product website printed on the label (www.xtandi.com) · page title "XTANDI® (enzalutamide) | Advanced Prostate Cancer Treatment" (checked 2026-11-06)
- Savings & Support · page title "Savings and Support Solutions | XTANDI® (enzalutamide)" (checked 2026-11-06)
7. Tafamidis · $3.2 billion combined spending
- Product website printed on the label (www.vyndaqel.com) · page title "VYNDAMAX® (tafamidis) Prescription Treatment for ATTR-CM | Safety Info" (checked 2026-11-06)
8. Cariprazine · $2.6 billion combined spending
- Product website printed on the label (www.vraylar.com) · page title "VRAYLAR® (cariprazine) for Bipolar I or Major Depressive Disorder" (checked 2026-11-06)
- Cost & Savings · page title "VRAYLAR® (cariprazine) Cost and Savings" (checked 2026-11-06)
- Get your savings card · page title "Sign Up for the VRAYLAR® (cariprazine) Savings Program" (checked 2026-11-06)
9. Valbenazine · $2.6 billion combined spending
- Product website printed on the label (www.ingrezza.com) · page title "Tardive Dyskinesia Treatment | INGREZZA® (valbenazine) capsules" (checked 2026-11-06)
- Savings & support · page title "Neurocrine Access Support | INGREZZA® (valbenazine) capsules for TD" (checked 2026-11-06)
10. Ruxolitinib · $2.5 billion combined spending
- Product website printed on the label (www.jakafi.com) · page title "Polycythemia Vera, Myelofibrosis, Acute & Chronic Graft-Versus-Host Disease | Jakafi®/Jakafi XR™ (ruxolitinib)" (checked 2026-11-06)
11. Ibrutinib · $2.4 billion combined spending
- Product website printed on the label (www.imbruvica.com) · page title "IMBRUVICA® (ibrutinib) | Official Patient Website" (checked 2026-11-06)
- Patient Support & Savings · page title "IMBRUVICA® By Your Side | IMBRUVICA® (ibrutinib)" (checked 2026-11-06)
- Explore Savings · page title "Affording IMBRUVICA® | IMBRUVICA® (ibrutinib)" (checked 2026-11-06)
12. Palbociclib · $2.3 billion combined spending
The label does not print a product website ClinDose could check. Ask the manufacturer or the specialty pharmacy about assistance, or see the foundations above.
13. Pomalidomide · $2.3 billion combined spending
The label does not print a product website ClinDose could check. Ask the manufacturer or the specialty pharmacy about assistance, or see the foundations above.
14. Nintedanib esylate · $2.2 billion combined spending
- Product website printed on the label (www.ofev.com/support) (checked 2026-11-06)
15. Human immunoglobulin g · $2.2 billion combined spending
The label does not print a product website ClinDose could check. Ask the manufacturer or the specialty pharmacy about assistance, or see the foundations above.
16. Upadacitinib · $2.0 billion combined spending
- Product website printed on the label (www.rinvoq.com) · page title "RINVOQ® (upadacitinib) for RA, PsA, AD, AS, nr-axSpA, UC, CD, pJIA & JPsA" (checked 2026-11-06)
- Cost & Savings · page title "RINVOQ® (upadacitinib) Cost" (checked 2026-11-06)
17. Macitentan · $1.5 billion combined spending
- Product website printed on the label (www.opsumit.com) · page title "OPSUMIT® (macitentan) Pulmonary Arterial Hypertension (PAH) Treatment" (checked 2026-11-06)
18. Apalutamide · $1.4 billion combined spending
- Product website printed on the label (www.erleada.com) · page title "Prostate Cancer Treatment | ERLEADA® (apalutamide)" (checked 2026-11-06)
19. Apremilast · $1.4 billion combined spending
The label does not print a product website ClinDose could check. Ask the manufacturer or the specialty pharmacy about assistance, or see the foundations above.
20. Cabozantinib · $1.3 billion combined spending
- Product website printed on the label (www.cabometyx.com) · page title "CABOMETYX® (cabozantinib) Patient Website" (checked 2026-11-06)
- Cost & Financial Support · page title "Cost & Financial Support | CABOMETYX® (cabozantinib)" (checked 2026-11-06)
21. Brexpiprazole · $1.3 billion combined spending
- Product website printed on the label (www.rexulti.com) · page title "REXULTI® (brexpiprazole) | Patient Information Website" (checked 2026-11-06)
22. Ixekizumab · $1.3 billion combined spending
The label does not print a product website ClinDose could check. Ask the manufacturer or the specialty pharmacy about assistance, or see the foundations above.
23. Selexipag · $1.2 billion combined spending
- Product website printed on the label (www.uptravi.com) · page title "Treatment with UPTRAVI | UPTRAVI (selexipag)" (checked 2026-11-06)
- Resources & Cost Support · page title "UPTRAVI Support Programs & Resources | UPTRAVI (selexipag)" (checked 2026-11-06)
24. Tofacitinib extended-release · $1.1 billion combined spending
- Product website printed on the label (www.sciegenpharm.com) · page title "ScieGen Pharmaceuticals – Generic Pharmaceutical" (checked 2026-11-06)
25. Abatacept · $1.1 billion combined spending
- Product website printed on the label (www.orencia.com) · page title "Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), & pJIA Treatment | ORENCIA® (abatacept)" (checked 2026-11-06)
- Savings & Support Program · page title "ORENCIA® Cost and Patient Assistance Programs | ORENCIA® (abatacept)" (checked 2026-11-06)
26. Emtricitabine and tenofovir alafenamide · $1.0 billion combined spending
- Product website printed on the label (www.descovy.com) · page title "DESCOVY for PrEP® (pre-exposure prophylaxis)" (checked 2026-11-06)
27. Ribociclib · $1.0 billion combined spending
- Product website printed on the label (www.kisqali.com) · page title "eBC and mBC Treatment | KISQALI® (ribociclib)" (checked 2026-11-06)
28. Elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide · $928 million combined spending
- Product website printed on the label (www.genvoya.com) (checked 2026-11-06)
29. Ofatumumab · $916 million combined spending
- Product website printed on the label (www.novartis.us) · page title "Novartis Pharmaceuticals United States of America" (checked 2026-11-06)
- Patient assistance · page title "Patient Assistance | Novartis U.S." (checked 2026-11-06)
30. Eltrombopag · $913 million combined spending
The label does not print a product website ClinDose could check. Ask the manufacturer or the specialty pharmacy about assistance, or see the foundations above.
31. Dolutegravir · $903 million combined spending
- Product website printed on the label (www.tivicay.com) · page title "A Treatment Option | TIVICAY (dolutegravir)" (checked 2026-11-06)
32. Sofosbuvir and velpatasvir · $852 million combined spending
- Product website printed on the label (www.epclusa.com) · page title "EPCLUSA® (sofosbuvir/velpatasvir) A Hep C Treatment Option | Patient Site" (checked 2026-11-06)
- Saving on EPCLUSA · page title "Save on the Cost of EPCLUSA® (sofosbuvir 400mg/velpatasvir 100mg) | Patient Site" (checked 2026-11-06)
- Co-pay Savings Eligibility · page title "EPCLUSA® Co-pay Coupon Eligibility | Patient Site" (checked 2026-11-06)
33. Dasatinib · $851 million combined spending
The label does not print a product website ClinDose could check. Ask the manufacturer or the specialty pharmacy about assistance, or see the foundations above.
34. Dolutegravir and lamivudine · $839 million combined spending
- Product website printed on the label (www.dovato.com) · page title "HIV-1 Treatment | DOVATO (dolutegravir/lamivudine)" (checked 2026-11-06)
- Medicine Savings · page title "Home | ViiVConnect" (checked 2026-11-06)
35. Riociguat · $803 million combined spending
The label does not print a product website ClinDose could check. Ask the manufacturer or the specialty pharmacy about assistance, or see the foundations above.
36. Glecaprevir and pibrentasvir · $768 million combined spending
- Product website printed on the label (www.mavyret.com) · page title "MAVYRET (glecaprevir/pibrentasvir) for Hepatitis C - Official Site" (checked 2026-11-06)
- Cost & Savings · page title "MAVYRET Cost, Savings Card and Insurance Information" (checked 2026-11-06)
- MAVYRET PATIENT SUPPORT · page title "MAVYRET Patient Support and Nurse Ambassador Program" (checked 2026-11-06)
37. Darunavir, cobicistat, emtricitabine, and tenofovir alafenamide · $749 million combined spending
The label does not print a product website ClinDose could check. Ask the manufacturer or the specialty pharmacy about assistance, or see the foundations above.
38. Cannabidiol · $727 million combined spending
- Product website printed on the label (www.epidiolex.com) · page title "EPIDIOLEX® (cannabidiol) for LGS, Dravet & TSC Seizures" (checked 2026-11-06)
39. Olaparib · $720 million combined spending
The label does not print a product website ClinDose could check. Ask the manufacturer or the specialty pharmacy about assistance, or see the foundations above.
40. Omalizumab · $686 million combined spending
- Product website printed on the label (www.xolair.com) · page title "XOLAIR® (omalizumab) | Allergic Asthma, CSU, CRSwNP & Food Allergy Treatment" (checked 2026-11-06)
41. Pimavanserin · $670 million combined spending
The label does not print a product website ClinDose could check. Ask the manufacturer or the specialty pharmacy about assistance, or see the foundations above.
42. Lumateperone · $596 million combined spending
- Product website printed on the label (www.caplyta.com) · page title "Patient Information | CAPLYTA® (lumateperone)" (checked 2026-11-06)
- Cost & Savings · page title "Cost & Savings | CAPLYTA® (lumateperone)" (checked 2026-11-06)
43. Emtricitabine, rilpivirine, and tenofovir alafenamide · $590 million combined spending
- Product website printed on the label (www.odefsey.com) (checked 2026-11-06)
44. Teduglutide · $583 million combined spending
- Product website printed on the label (www.gattex.com) · page title "GATTEX® (teduglutide) for Short Bowel Syndrome (SBS)" (checked 2026-11-06)
45. Aripiprazole lauroxil · $577 million combined spending
- Product website printed on the label (www.aristada.com) · page title "ARISTADA® (aripiprazole lauroxil)| Official Patient Site" (checked 2026-11-06)
46. Teriparatide · $523 million combined spending
The label does not print a product website ClinDose could check. Ask the manufacturer or the specialty pharmacy about assistance, or see the foundations above.
47. Nilotinib · $521 million combined spending
The label does not print a product website ClinDose could check. Ask the manufacturer or the specialty pharmacy about assistance, or see the foundations above.
48. Dolutegravir and rilpivirine · $518 million combined spending
- Product website printed on the label (www.juluca.com) (checked 2026-11-06)
49. Tocilizumab · $496 million combined spending
- Product website printed on the label (www.actemra.com) · page title "RA, GCA, SSc-ILD, SJIA, PJIA, COVID-19 Treatment | ACTEMRA® (tocilizumab)" (checked 2026-11-06)
- financial assistance · page title "Financial Assistance Options | ACTEMRA® (tocilizumab)" (checked 2026-11-06)
50. Axitinib · $489 million combined spending
- Product website printed on the label (www.inlyta.com) · page title "INLYTA® (axitinib) Home Page | Safety Info" (checked 2026-11-06)
- Financial Assistance · page title "Financial Assistance For INLYTA® (axitinib) | Safety Info" (checked 2026-11-06)
- SIGN UP for co-pay assistance · page title "Sign Up | Patient Support | Pfizer Oncology Together" (checked 2026-11-06)
Ranking: Medicare Part D Spending by Drug 2024 and Medicaid Spending by Drug 2024 (CMS). Directory checked 2026-11-06; links are re-checked monthly and hidden when a page stops loading.
For licensed clinicians. Use with clinical judgment.